glp-1 obesity drug news updates How Supply and Demand for Weight Loss Drugs is Playing Out in 2026 The GLP-1 revolution: What UAB

Read more about the new GLP-1 pill that outperformed oral semaglutide in a recent Phase III trial.

however, this contradicts established trial data favoring SGLT2 inhibitors for heart failure and should be interpreted cautiously due to possible residual confounding

Notice subtle shifts in appetite, cravings, and portion size

GLP-1 2.0: where will the next wave of value come from

Some studies link GLP-1 drugs for diabetes with neuroprotective benefits but others say that some of these drugs may increase depression risk, a new review concludes.

With incretin-based drugs, much of the reported lean mass loss may not be skeletal muscle, but some is